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of hyperglycemia remains unproven. An association between glycemia and mortality would
provide compelling evidence to support glucose lowering in cystic ﬁbrosis–related diabetes
(CFRD).
RESEARCH DESIGN AND METHODS—Using the U.K. Cystic Fibrosis Registry, we
analyzed longitudinal data from 2006 to 2009 in 520 individuals with diabetes. We tested the
association between HbA1c and mortality.
RESULTS—During a median follow-up of 2 years, 36 patients died. The median value of
HbA1c was higher in those who died (7.3%) than in those who did not (6.7%). An HbA1c value
of $6.5% was associated with a threefold increased risk of death (hazard ratio 3.2 [95% CI 1.4–
7.3]; P = 0.005) independent of potential confounders.
CONCLUSIONS—Hyperglycemia trebles the risk of death in patients with CFRD. These
ﬁndings provide epidemiologic support for continued efforts to improve glycemic control.
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D
iabetes frequently complicates cys-
tic ﬁbrosis. Cystic ﬁbrosis–related
diabetes (CFRD) has an incidence
in teenagers of up to 6% per year and a
prevalence in adults of .30% (1,2). Di-
abetes further elevates the already high
mortality rates in cystic ﬁbrosis (3–5). In
individuals without cystic ﬁbrosis, diabe-
tes increases the risk of death, and in in-
dividuals with diabetes, hyperglycemia
increasestheriskofdeath(6,7).However,
no study of CFRD using national data
has investigated whether hyperglycemia,
per se, increases the risk of death; likewise,
no trial has tested whether controlling
blood glucose prolongs survival. Proving
an association between glycemia and mor-
tality in cystic ﬁbrosis would provide com-
pelling observational evidence to inform
clinical practice. Using the U.K. Cystic
Fibrosis Registry, we performed longitu-
dinal analyses to test the association be-
tween glycemia, as measured by HbA1c,
and mortality in individuals with CFRD.
RESEARCH DESIGN AND
METHODS—The U.K. Cystic Fibrosis
Registry collects clinical data from cystic
ﬁbrosis specialist clinics around the U.K.
Since 2006, the U.K. Cystic Fibrosis Reg-
istry has recorded HbA1c.W ep e r f o r m e d
survival analyses for individuals with dia-
betes from the ﬁrst clinical visit in 2006 to
the time of death or censoring (1 August
2009). Diabetes was deﬁned by physician
diagnosis and/or oral glucose tolerance
testing with values of 7 mmol/L fasting or
11.1 mmol/L at 2 h. Of 5,810 individuals
who had clinical reviews from 2006 on-
ward, we analyzed data from 520 of 912
individuals with diabetes for whom full
clinical data, including at least one mea-
surement of HbA1c, were available. HbA1c
was measured in local, accredited National
Health Service laboratories.
We tested the association between
glycemia, measured at the ﬁrst clinical
visit (baseline) and categorized as an
HbA1c $6.5 vs. ,6.5%, and mortality.
An HbA1c value of 6.5% approximates
the median value and reﬂects excellent
glycemic control. Potential confounders,
previously identiﬁed as plausibly related
toboththeincidenceofdiabetesandmor-
tality (1,3) and measured at baseline, in-
cluded age; sex; BMI z score; pulmonary
function, as measured by percent pre-
dicted forced expiratory volume at 1 s
(FEV1); and use of corticosteroids (either
oralorinhaled).Theregistrydidnotpro-
videinformationondurationofdiabetes.
We measured time to event from regis-
tration to death or censoring and mod-
eled the data using proportional hazards
regression with HbA1c as the main expo-
sure variable in univariate and multivar-
iate models. Death was the dependent
variable.
RESULTS—The median age of patients
was 25.0 years (range 0.4–67.8), and
HbA1c was 6.7% (4.9–17.0). A total of
84% of patients received treatment to
lower blood glucose. Patients with
HbA1c values $6.5%, relative to those
with values ,6.5%, did not differ signif-
icantly with respect to age, sex, BMI, pul-
monary function, or use of corticosteroids.
During a median follow-up of 2.01 years
(0.02–3.53), 36 patients died. The median
value of HbA1c was higher in those who
died (7.3%) than in those who did not
(6.7%) (Table 1). Table 1 contrasts the
characteristics of the patients who died
with those who did not. An HbA1c value
of $6.5% was associated with a threefold
increased risk of death (hazard ratio 3.2
[95% CI 1.4–7.3]; P = 0.005). The associ-
ation did not change when controlling for
risk factors for death conceivably related
to hyperglycemia (age, sex, BMI z score,
FEV1, and use of corticosteroids). In mul-
tivariate analysis, HbA1c $6.5% was asso-
ciated with a hazard ratio of 3.3 (95% CI
1.4–7.5; P =0 . 0 0 5 ) .
Respiratory disease was the number
one cause of death. Among those who
died, the proportion who died from re-
spiratory disease did not differ between
those with HbA1c values .6.5 or ,6.5%,
comprising 20 of 29 (69%) deaths in in-
dividuals with HbA1c values at or above
6.5% and 4 of 7 (57%) deaths in individ-
uals with lower values.
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BRIEF REPORTCONCLUSIONS—This study shows
that among individuals with cystic ﬁbro-
sis and diabetes, those with HbA1c levels
above the clinically deﬁned target of
6.5% are more likely to die than those
with lower values, an observation not ac-
counted for by established risk factors
for death. Whereas diabetes in cystic ﬁ-
brosis is known to increase the risk of
death, hyperglycemia in cystic ﬁbrosis–
related diabetes is not. We are not aware
of another study that has shown an asso-
ciation between HbA1c, a validated mea-
sure of glycemia in cystic ﬁbrosis (8),
and death. In Minnesota, of adults with
CFRD,morepatientswhodevelopedfast-
ing hyperglycemia died during the study
period (26% [n = 8]) compared with 7%
(n = 6) of patients who did not develop
fasting hyperglycemia, suggesting a role
for hyperglycemia (5).
In a few individuals, an elevated
HbA1c value may have reﬂected their ill-
ness and impending death. There were
too few individuals who died within
months of measuring their HbA1c to test
this possibility. In addition, other factors
may have confounded the ﬁndings of this
study. However, we observed no change
in the magnitude of the increase in risk
associated with hyperglycemia when tak-
ing into account well established risks
for morbidity in cystic ﬁbrosis. It also is
possible, given the median value of
HbA1c, that some included individuals
did not have diabetes. Nonetheless, it is
likely that they had dysglycemia, and, in
any event, this misclassiﬁcation would
have minimally biased our ﬁndings.
Excluded from this study were a sub-
stantial proportion of individuals who
had diabetes but who did not have avail-
able values of HbA1c and other clinical
data. Of note, included individuals were
not more likely to die than excluded in-
dividuals (data not shown). Our results,
therefore, are likely generalizable.
This study shows that the increased
mortality with hyperglycemia occurs for
respiratory disease, which is not classi-
cally considered a complication of diabe-
tes. The many potential mechanisms may
include poorer nutrition, greater catab-
olism, and higher risks of infection. In
cystic ﬁbrosis, blood glucose values cor-
relatewithairwayglucoseconcentrations,
and these increase the probability of
colonization with pathogens (9).
No randomized trial has yet ad-
dressedglucoselowering incysticﬁbrosis
with the a priori outcome of extending
life. In the absence of trials, this report
provides epidemiologic support for con-
tinued efforts to improve glycemic con-
trol in CFRD.
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Table 1—Characteristics of patients with CFRD by survival
Characteristic Alive Dead P
n 484 36
Age (years) 26.6 6 9.5 28.8 6 9.6 0.18
Female (%) 44.2 58.3 0.14
HbA1c (%) 6.6 (5.9–7.9) 7.3 (6.6–8.3) 0.009*
BMI z score 20.35 6 1.18 21.14 6 1.21 ,0.001
FEV1 (% predicted) 54.3 6 22.7 33.4 6 19.5 ,0.001
Using prednisolone (%) 19.0 27.8 0.29
Data are means 6SD or median (interquartile range),unless otherwise indicated. *TestedusingtheKruskal-
Wallis one-way ANOVA.
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